查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1908159

阿茲海默症診斷市場規模、佔有率和趨勢分析報告：按診斷技術、類型、最終用途、地區和細分市場預測（2026-2033 年）

Alzheimer's Disease Diagnostics Market Size, Share & Trends Analysis Report By Diagnostics Technique, By Type, By End User, By Region And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

阿茲海默症診斷市場概覽

全球阿茲海默症診斷市場預計到 2025 年價值 92.2 億美元，預計到 2033 年將達到 215.4 億美元。

預計從 2026 年到 2033 年，該市場將以 11.23% 的複合年成長率成長。阿茲海默症(AD) 盛行率的上升、生物標記在疾病診斷中的應用日益廣泛、個人化產品的普及以及醫學影像技術的進步，都是推動阿茲海默症診斷需求成長的部分因素。

政府投資和研發投入的增加正在推動市場進一步成長。阿茲海默症盛行率的上升是市場成長的主要驅動力。隨著世界人口老化，對早期精準診斷工具的需求持續成長。根據阿茲海默症協會2024年的報告，失智症的風險老齡化成長而增加，預計美國阿茲海默症患者人數將顯著成長。到2050年，65歲及以上人口預計將達到8,200萬，高於2022年的5,800萬。到2030年，所有嬰兒潮世代（1946年至1964年出生）都將年滿65歲，這使得該年齡層成為老年失智症失智症風險最高的族群。

近年來，針對阿茲海默症根本病因的新療法研發取得了顯著進展。 2023年1月，美國食品藥物管理局（FDA）加速核准了由衛材Eisai , Ltd.）和渤健公司（Biogen）聯合研發的藥物lecanemab上市。Eisai已在日本申請生產和銷售核准，並獲得了厚生勞動省（MHLW）的優先審查資格。然而，這些藥物的有效應用和廣泛推廣需要能夠檢測大腦中BETA-澱粉樣蛋白（ABETA）累積的技術。傳統的檢測方法，例如腦脊髓液（CSF）檢測和澱粉樣蛋白PET掃描，費用昂貴且具有侵入性，因此人們越來越需要更簡單、更非侵入性的診斷方法。

阿茲海默症在全球範圍內日益加重，因此早期發現和準確診斷顯得尤為重要。基因組學、蛋白質組學和代謝體學的進步正在拓展生物標記在疾病診斷中的應用。特別是，利用正子斷層掃描（PET）影像技術檢測腦脊髓液中的BETA-澱粉樣蛋白和Tau蛋白等生物標記物，在阿茲海默症診斷中發揮關鍵作用。此外，各公司正在推出創新的生物標記檢測方法，以支援正在進行的臨床試驗。 2024年3月，LabCorp推出了pTau217血液生物標記檢測，旨在加快阿茲海默症的診斷速度，並提高臨床檢測效率。該檢測有望提高阿茲海默症檢測的準確性和速度，從而實現及時治療和疾病管理。

個人化醫療的興起凸顯了生物標記在患者分類、治療選擇和治療後續觀察中的重要性。這一趨勢預計將推動生物標記市場的擴張。 2023年發表在《阿茲海默症雜誌》上的一項研究強調了精準醫療的作用，精準醫療會考慮遺傳、環境和生活方式因素對疾病進展的影響。同樣，2021年10月的一項研究提案，Bumetanide（一種FDA核准的口服利尿劑）可能是一種治療方法阿茲海默症藥物。一項由美國國家老齡研究所（NIA）資助的研究分析了腦組織樣本和FDA認證核可藥，以探索現有藥物再利用的潛力，凸顯了精準醫療在治療阿茲海默症的潛力。

影像分析和機器學習演算法的進步正在透過神經影像成像技術提高阿茲海默症診斷的準確性和可靠性。診斷方法正從傳統的認知評估發展到先進的神經影像和腦脊髓液（CSF）檢測，從而能夠更早發現疾病。 2023年6月，羅氏公司獲得美國食品藥物管理局（FDA）核准，其研發的腦脊髓液檢測可測量55歲及以上人群中BETA-澱粉樣蛋白和Tau蛋白的水平，這兩種蛋白是阿茲海默症病理的關鍵生物標記。此檢測有助於及時診斷和製定治療方案。這些技術進步對於改善阿茲海默症的檢測和管理至關重要。

持續的研究和技術創新正在推動阿茲海默症診斷和治療市場的擴張。各公司不斷推出新的檢測方法和產品，同時也積極進行策略合作、併購和投資。 2024年2月，《MedPage Today》的一篇報導重點介紹了血液生物標記在阿茲海默症研究和臨床應用中的診斷潛力。主要企業正致力於推動血液生物標記技術的進步，以提升全球診斷能力。 2023年8月，C2N Diagnostics公司發布了PrecivityAD2血液檢測，其準確性可與PET掃描和腦脊髓液檢測相媲美。該檢測旨在評估認知能力下降和阿茲海默症症狀的患者，從而推動該領域診斷技術的進一步發展。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章阿茲海默症診斷市場的變數、趨勢和範圍

  • 市場譜系展望
    • 母市場展望
    • 相關及附隨市場展望
  • 市場動態
  • 阿茲海默症診斷市場分析工具
    • 產業分析：波特五力模型
    • PESTEL 分析
  • 阿茲海默症診斷市場：應用案例分析

第4章阿茲海默症診斷市場：診斷技術估算與趨勢分析

  • 按診斷技術分類的市場佔有率（2025 年和 2033 年）
  • 全球阿茲海默症診斷市場：按診斷技術分類的展望
  • 市場規模、預測與趨勢分析（2021-2033）
  • 生物標記
    • 腦脊髓液生物標記
    • 血液生物標記
  • 成像技術
  • 基因檢測
  • 認知功能評估測試

第5章阿茲海默症診斷市場：按類型分類的估計和趨勢分析

  • 按類型分類的市場佔有率（2025 年和 2033 年）
  • 全球阿茲海默症診斷市場：按類型分類的展望
  • 市場規模、預測與趨勢分析（2021-2033）
  • 分診
  • 診斷
  • 篩檢

第6章：阿茲海默症診斷市場：依最終用途分類的估計與趨勢分析

  • 按最終用途分類的市場佔有率（2025 年和 2033 年）
  • 全球阿茲海默症診斷市場：終端用戶展望
  • 市場規模、預測與趨勢分析（2021-2033）
  • 醫院
  • 診斷實驗室
  • 學術和研究機構

第7章阿茲海默症診斷市場：區域、估計和趨勢分析

  • 區域市場佔有率分析（2025 年和 2033 年）
  • 區域市場概覽
  • 全球市場概覽（按地區分類）
  • 市場規模及預測趨勢分析，2021-2033年
  • 北美洲
    • 北美：SWOT 分析
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 歐洲：SWOT分析
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 亞太地區：SWOT分析
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 拉丁美洲：SWOT分析
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 中東和非洲：SWOT 分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭情勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商概況
    • 主要經銷商和通路合作夥伴名單
    • 主要公司市佔率分析，2025 年
    • Quest Diagnostics Incorporated
    • Laboratory Corporation of America Holdings
    • F. Hoffmann-La Roche Ltd.
    • Siemens Healthineers AG
    • C2N diagnostics
    • FujireBio
    • Bristol Myers Squibb Company
    • Quanterix
    • Sysmex
    • Lantheus
Product Code: GVR-4-68040-323-7

Alzheimer's Disease Diagnostics Market Summary

The global Alzheimer's disease diagnostics market size was estimated at USD 9.22 billion in 2025 and is expected to reach USD 21.54 billion by 2033, projected to grow at a CAGR of 11.23% from 2026 to 2033. Increasing prevalence of Alzheimer's Disease (AD), growing use of biomarkers in disease diagnostics, growing adoption of personalized products, and increasing technological advancements in medical imaging are some of the factors expected to drive the demand for Alzheimer's diagnostics.

Increasing government investments and R&D studies is further propelling growth. The rising prevalence of Alzheimer's disease is a key driver of market growth. As the global population ages, the demand for early and accurate diagnostic tools continues to increase. According to the 2024 Alzheimer's Association, dementia risk rises with age, and the number of Americans with Alzheimer's is expected to grow significantly. By 2050, the population aged 65 and older is projected to reach 82 million, up from 58 million in 2022. By 2030, all baby boomers (born between 1946 and 1964) will be 65 or older, the age group most susceptible to Alzheimer's dementia.

In recent years, there has been significant progress in developing novel therapeutic drugs targeting the root causes of Alzheimer's disease. In January 2023, the U.S. FDA granted accelerated approval to lecanemab, a treatment co-developed by Eisai Co., Ltd. and Biogen Inc. Eisai also applied for manufacturing and marketing approval in Japan, where the drug received priority review from the Ministry of Health, Labour and Welfare (MHLW). However, effective use and distribution of these drugs require technology to detect amyloid-beta (AB) accumulation in the brain. Conventional testing methods, such as cerebrospinal fluid (CSF) testing and amyloid PET scans, are costly and invasive, increasing the demand for simpler, less invasive diagnostic approaches.

The growing global burden of Alzheimer's has intensified the need for early detection and precise diagnosis. Advances in genomics, proteomics, and metabolomics have expanded the use of biomarkers in disease diagnostics. Biomarkers, particularly those detecting amyloid-beta and tau proteins in CSF through positron emission tomography (PET) imaging, play a crucial role in Alzheimer's diagnosis. In addition, companies are launching innovative biomarker tests to support ongoing clinical trials. In March 2024, Labcorp introduced the pTau217 blood biomarker test, designed to accelerate Alzheimer's diagnosis and improve clinical trial efficiency. This test is expected to enhance the accuracy and speed of detecting Alzheimer's, ensuring timely treatment and disease management.

The rise of personalized medicine has underscored the importance of biomarkers in patient categorization, treatment selection, and therapeutic monitoring. This trend is expected to drive the biomarkers market's expansion. A 2023 study published in the Journal of Alzheimer's Disease emphasized the role of precision medicine in Alzheimer's, considering genetic, environmental, and lifestyle factors in disease progression. Similarly, an October 2021 study suggested bumetanide, an FDA-approved oral diuretic, as a potential treatment for Alzheimer's. Research funded by the National Institute on Aging (NIA) analyzed brain tissue samples and FDA-approved drugs to explore repurposing opportunities, highlighting precision medicine's potential in Alzheimer's treatment.

Advancements in image analysis and machine learning algorithms have enhanced the accuracy and reliability of Alzheimer's diagnostics through neuroimaging techniques. Diagnostic approaches have evolved from traditional cognitive assessments to advanced neuroimaging and CSF assays, allowing for early disease identification. In June 2023, Roche received FDA clearance for its CSF assay, which aids in timely diagnosis and treatment decision-making by measuring beta-amyloid and tau protein levels, two key biomarkers of Alzheimer's pathology, in individuals aged 55 and older. These technological advancements are crucial for improving Alzheimer's detection and management.

Ongoing research and technological innovations are driving the expansion of the Alzheimer's diagnostics and therapeutics market. Companies continue to introduce new tests and products while engaging in strategic collaborations, mergers, and investments. A February 2024 MedPage Today article highlighted the diagnostic potential of blood biomarkers in Alzheimer's research and clinical applications. Key industry players are advancing blood biomarker technologies to enhance global diagnostic capabilities. In August 2023, C2N Diagnostics launched the PrecivityAD2 blood test, designed to match the accuracy of PET scans and CSF tests. This test aims to assess patients with cognitive decline and Alzheimer's symptoms, further strengthening diagnostic advancements in the field.

Global Alzheimer's Disease Diagnostics Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global Alzheimer's disease diagnostics market report on the basis of diagnostics technique, type, end use, and region.

  • Diagnostics Technique Outlook (Revenue, USD Million, 2021 - 2033)
  • Biomarkers
    • CSF Biomarkers
    • Blood-Based Biomarkers
  • Imaging Techniques
  • Genetic Testing
  • Cognitive Assessment Tests
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Triage
  • Diagnosis
  • Screening
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Diagnostic Laboratories
  • Academic and Research Institutes
  • Regional Outlook (Revenue in USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Diagnostics Technique
    • 1.2.2. Type
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Diagnostics Technique outlook
    • 2.2.2. Type outlook
    • 2.2.3. End Use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Alzheimer's Disease Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of Alzheimer disease
      • 3.2.1.2. Increasing use of biomarkers in diagnosis
      • 3.2.1.3. Growing adoption of personalized products
      • 3.2.1.4. Growing R&D studies and government investments
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Stringent regulations
  • 3.3. Alzheimer's Disease Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
  • 3.4. Alzheimer's Disease Diagnostics Market: Case Study Analysis

Chapter 4. Alzheimer's Disease Diagnostics Market: Diagnostics Technique Estimates & Trend Analysis

  • 4.1. Diagnostics Techniques Market Share, 2025 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Alzheimer's Disease Diagnostics Market: Diagnostics Technique Movement Analysis
  • 4.4. Alzheimer's Disease Diagnostics Market Size & Trend Analysis, by diagnostic technique, 2021 to 2033 (USD Million)
  • 4.5. Biomarker
    • 4.5.1. Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2. CSF Biomarkers
      • 4.5.2.1. CSF Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3. Blood Based Biomarker
      • 4.5.3.1. Blood Based Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Imaging Techniques
    • 4.6.1. Imaging Techniques Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Genetic Testing
    • 4.7.1. Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.8. Cognitive Assessment Tests
    • 4.8.1. Cognitive Assessment Tests Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Alzheimer's Disease Diagnostics Market: Type Estimates & Trend Analysis

  • 5.1. Type Market Share, 2025 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global Alzheimer's Disease Diagnostics Market by Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.5. Triage
    • 5.5.1. Triage Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.6. Diagnosis
    • 5.6.1. Diagnosis Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7. Screening
    • 5.7.1. Screening Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Alzheimer's Disease Diagnostics Market: End Use Estimates & Trend Analysis

  • 6.1. End Use Market Share, 2025 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Global Alzheimer's Disease Diagnostics Market by End Use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.5. Hospitals
    • 6.5.1. Hospitals Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Diagnostic Laboratories
    • 6.6.1. Diagnostic Laboratories Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7. Academic and Research Institutes
    • 6.7.1. Academic and Research Institutes Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Alzheimer's Disease Diagnostics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2025 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033
  • 7.5. North America
    • 7.5.1. North America: SWOT Analysis
    • 7.5.2. U.S.
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/Reimbursement
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.3. Canada
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/Reimbursement
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.4. Mexico
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/Reimbursement
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Europe
    • 7.6.1. Europe: SWOT Analysis
    • 7.6.2. UK
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/Reimbursement
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.3. Germany
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/Reimbursement
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.4. France
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/Reimbursement
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.5. Italy
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/Reimbursement
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.6. Spain
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/Reimbursement
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.7. Norway
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/Reimbursement
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.8. Sweden
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/Reimbursement
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.9. Denmark
      • 7.6.9.1. Key country dynamics
      • 7.6.9.2. Regulatory framework/Reimbursement
      • 7.6.9.3. Competitive scenario
      • 7.6.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Asia Pacific: SWOT Analysis
    • 7.7.2. Japan
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/Reimbursement
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.3. China
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/Reimbursement
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.4. India
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/Reimbursement
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.5. Australia
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/Reimbursement
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.6. South Korea
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/Reimbursement
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.7. Thailand
      • 7.7.7.1. Key country dynamics
      • 7.7.7.2. Regulatory framework/Reimbursement
      • 7.7.7.3. Competitive scenario
      • 7.7.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Latin America: SWOT Analysis
    • 7.8.2. Brazil
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/Reimbursement
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/Reimbursement
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9. MEA
    • 7.9.1. MEA: SWOT Analysis
    • 7.9.2. South Africa
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/Reimbursement
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.3. Saudi Arabia
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/Reimbursement
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.4. UAE
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/Reimbursement
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.5. Kuwait
      • 7.9.5.1. Key country dynamics
      • 7.9.5.2. Regulatory framework
      • 7.9.5.3. Competitive scenario
      • 7.9.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2025
    • 8.3.4. Quest Diagnostics Incorporated
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Services benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Laboratory Corporation of America Holdings
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Services benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. F. Hoffmann-La Roche Ltd.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Services benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Siemens Healthineers AG
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Services benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. C2N diagnostics
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Services benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. FujireBio
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Services benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Bristol Myers Squibb Company
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Services benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Quanterix
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Services benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Sysmex
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Services benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Lantheus
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Services benchmarking
      • 8.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Alzheimer's disease diagnostics market, by region, 2021 - 2033 (USD Million)
  • Table 3 North America Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 4 North America Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 5 North America Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 6 U.S. Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 7 U.S. Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 8 U.S. Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 9 Canada Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 10 Canada Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 11 Canada Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 12 Mexico Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 13 Mexico Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 14 Mexico Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 15 Europe Alzheimer's disease diagnostics market, by region, 2021 - 2033 (USD Million)
  • Table 16 Europe Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 17 Europe Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 18 Europe Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 19 Germany Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 20 Germany Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 21 Germany Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 22 UK Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 23 UK Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 24 UK Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 25 France Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 26 France Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 27 France Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 28 Italy Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 29 Italy Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 30 Italy Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 31 Spain Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 32 Spain Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 33 Spain Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 34 Denmark Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 35 Denmark Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 36 Denmark Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 37 Sweden Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 38 Sweden Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 39 Sweden Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 40 Norway Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 41 Norway Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 42 Norway Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 43 Asia Pacific Alzheimer's disease diagnostics market, by region, 2021 - 2033 (USD Million)
  • Table 44 Asia Pacific Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 45 Asia Pacific Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 46 Asia Pacific Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 47 China Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 48 China Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 49 China Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 50 Japan Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 51 Japan Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 52 Japan Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 53 India Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 54 India Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 55 India Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 56 South Korea Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 57 South Korea Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 58 South Korea Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 59 Australia Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 60 Australia Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 61 Australia Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 62 Thailand Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 63 Thailand Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 64 Thailand Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 65 Latin America Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 66 Latin America Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 67 Latin America Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 68 Brazil Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 69 Brazil Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 70 Brazil Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 71 Argentina Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 72 Argentina Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 73 Argentina Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 74 MEA Alzheimer's disease diagnostics market, by region, 2021 - 2033 (USD Million)
  • Table 75 MEA Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 76 MEA Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 77 MEA Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 78 South Africa Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 79 South Africa Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 80 South Africa Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 81 Saudi Arabia Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 82 Saudi Arabia Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 83 Saudi Arabia Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 84 UAE Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 85 UAE Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 86 UAE Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 87 Kuwait Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 88 Kuwait Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Alzheimer's disease diagnostics market: market outlook
  • Fig. 14 Alzheimer disease diagnostics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Alzheimer's disease diagnostics market driver impact
  • Fig. 20 Alzheimer's disease diagnostics market restraint impact
  • Fig. 21 Alzheimer's disease diagnostics market strategic initiatives analysis
  • Fig. 22 Alzheimer's disease diagnostics market: Diagnostics technique movement analysis
  • Fig. 23 Alzheimer's disease diagnostics market: Diagnostics technique outlook and key takeaways
  • Fig. 24 Biomarkers market estimates and forecast, 2021 - 2033
  • Fig. 25 CSF biomarkers estimates and forecast, 2021 - 2033
  • Fig. 26 Blood based biomarkers market estimates and forecast, 2021 - 2033
  • Fig. 27 Imaging techniques estimates and forecast, 2021 - 2033
  • Fig. 28 Genetic testing market estimates and forecast, 2021 - 2033
  • Fig. 29 Cognitive assessment tests market estimates and forecasts, 2021 - 2033
  • Fig. 30 Alzheimer's disease diagnostics market: Test type movement analysis
  • Fig. 31 Alzheimer's disease diagnostics market: Test type outlook and key takeaways
  • Fig. 32 Triage market estimates and forecasts, 2021 - 2033
  • Fig. 33 Diagnosis market estimates and forecasts, 2021 - 2033
  • Fig. 34 Screening market estimates and forecasts, 2021 - 2033
  • Fig. 35 Alzheimer's disease diagnostics market: End use movement analysis
  • Fig. 36 Alzheimer's disease diagnostics market: End- use outlook and key takeaways
  • Fig. 37 Hospitals market estimates and forecasts, 2021 - 2033
  • Fig. 38 Diagnostic laboratories market estimates and forecasts, 2021 - 2033
  • Fig. 39 Academic and research institutes market estimates and forecasts, 2021 - 2033
  • Fig. 40 Global Alzheimer's disease diagnostics market: Regional movement analysis
  • Fig. 41 Global Alzheimer's disease diagnostics market: Regional outlook and key takeaways
  • Fig. 42 Global Alzheimer's disease diagnostics market share and leading players
  • Fig. 43 North America, by country
  • Fig. 44 North America Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 45 U.S. key country dynamics
  • Fig. 46 U.S. Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 47 Canada key country dynamics
  • Fig. 48 Canada Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 49 Mexico key country dynamics
  • Fig. 50 Mexico Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 51 Europe Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 52 UK key country dynamics
  • Fig. 53 UK Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 54 Germany key country dynamics
  • Fig. 55 Germany Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 56 France key country dynamics
  • Fig. 57 France Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 58 Italy key country dynamics
  • Fig. 59 Italy Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 60 Spain key country dynamics
  • Fig. 61 Spain Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 62 Denmark key country dynamics
  • Fig. 63 Denmark Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 64 Sweden key country dynamics
  • Fig. 65 Sweden Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 66 Norway key country dynamics
  • Fig. 67 Norway Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 68 Asia Pacific Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 69 China key country dynamics
  • Fig. 70 China Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 71 Japan key country dynamics
  • Fig. 72 Japan Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 73 India key country dynamics
  • Fig. 74 India Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 75 Thailand key country dynamics
  • Fig. 76 Thailand Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 77 South Korea key country dynamics
  • Fig. 78 South Korea Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 79 Australia key country dynamics
  • Fig. 80 Australia Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 81 Latin America Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 82 Brazil key country dynamics
  • Fig. 83 Brazil Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 84 Argentina key country dynamics
  • Fig. 85 Argentina Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 86 Middle East and Africa Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 87 South Africa key country dynamics
  • Fig. 88 South Africa Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 89 Saudi Arabia key country dynamics
  • Fig. 90 Saudi Arabia Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 91 UAE key country dynamics
  • Fig. 92 UAE Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 93 Kuwait key country dynamics
  • Fig. 94 Kuwait Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 95 Market share of key market players- Alzheimer's disease diagnostics market